SymBio Signs Worldwide Exclusive License Agreement with Chimerix to Develop and Commercialize Brincidofovir
Shots:
- Chimerix to receive $5M up front- up to $150M as clinical- regulatory & commercial milestone with royalties on global sales of Brincidofovir. SymBio to get exclusive WW rights to develop- manufacture & commercialize Brincidofovir in all human indications excluding prevention and treatment of smallpox and is responsible for all development- manufacturing & commercialization activities
- The collaboration will allow Chimerix to focus on the development of Dociparstat sodium (CX-01) in a P-III study as a 1L treatment for AML and provide an opportunity to participate in the value of ongoing development of Brincidofovir through milestones & royalties
- Chimerix’s Brincidofovir (BCV- CMX001) is an anti-viral therapy being developed for the treatment of cytomegalovirus- adenovirus- smallpox- and ebolavirus infections and is a prodrug of cidofovir
Click here to read full press release/ article | Ref: Chimerix | Image: Pappas Capital
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com